|

Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes

RECRUITINGN/ASponsored by Western Sydney Local Health District
Actively Recruiting
PhaseN/A
SponsorWestern Sydney Local Health District
Started2026-03-31
Est. completion2027-09-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Premature ventricular complexes (PVCs) are extra, abnormal heart beats arising from the ventricles of the heart and are the most common ventricular arrhythmia. PVCs can be treated with medication or with a procedure called catheter ablation. It is not known which provides a better cure or provides better quality of life. The purpose of this research project is to study the best way to treat PVCs by comparing the use of medication to catheter ablation to assess which approach is better at reducing symptoms and improving quality of life.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria

1. PVC burden of ≥10% as determined by ≥24-hour heart rhythm monitoring.
2. Normal left ventricular ejection fraction, defined as ejection fraction ≥50%.
3. Aged ≥18 years.
4. Symptoms due to PVCs according to the judgement of the treating physician.

Exclusion Criteria

1. Unable or unwilling to provide informed consent or comply with study requirements including study investigations, follow-up, medical adherence and completion of the assigned intervention.
2. Women who are pregnant or breastfeeding.
3. Life expectancy ≤12 months.
4. Ventricular tachycardia (VT), defined as spontaneous VT lasting ≥30 seconds, haemodynamically unstable VT of any duration, inducible sustained VT during any electrophysiology study, or ≥10 episodes of non-sustained VT (\>5 consecutive beats lasting ≤30 seconds) within 24 hours on heart rhythm monitoring.
5. Previous catheter ablation for ventricular arrhythmia.
6. Clinically significant coronary artery disease, defined as a history of myocardial infarction, prior coronary revascularisation, inducible ischaemia on functional testing or obstructive coronary artery disease on coronary imaging. Any type of coronary assessment is permitted, although computed tomography coronary angiography is encouraged.
7. Moderate or greater valvular heart disease.
8. Known non-ischaemic or ischaemic cardiomyopathy or evidence of myocardial scar on cardiac magnetic resonance imaging suggestive of structural heart disease.
9. Known cardiac channelopathies including catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome and long- or short-QT syndrome.
10. In the opinion of the investigator or responsible physician, participation would not be in the patient's best interest or the patient would be unable to complete study procedures because of concomitant illness, physical impairment or mental condition.

Conditions4

Heart DiseasePremature Ventricular BeatsPremature Ventricular ComplexesPremature Ventricular Contraction (PVC)

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.